Treatment of Corneal Neovascularization With Topical Pazopanib
Status:
Completed
Trial end date:
2012-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the safety and efficacy of a drug [Pazopanib
(Votrient)] as a treatment for corneal neovascularization. The cornea is the clear, central
portion of the eye and neovascularization means blood vessel growth. The cornea is typically
avascular, or without blood vessels. Corneal neovascularization in the cornea and can put
vision at risk. Numerous diseases of the cornea such as inflammation, ischemia (restriction
of blood supply), infection, degeneration (or deterioration), trauma, or corneal stem cell
deficiency can lead to corneal neovascularization. This major ocular complication can lead to
corneal scarring, edema (swelling), lipid deposits, and inflammation that may significantly
alter your vision. In addition, it worsens the outcome of potential future treatments, such
as a corneal transplant. A corneal transplant is a treatment that many patients with severe
corneal disease may ultimately need.